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Abstract  
The present review provides an overview of methods and techniques for studying interactions 
of micro- and nanoparticulate drug delivery system with mucus. Nanocarriers trapped by 
mucus are featuring a change in particle size and zeta potential that can be utilized to predict 
their mucus permeation behavior. Furthermore, interactions between nanoparticulate drug 
delivery systems and mucus layer modify the  viscoelasticity of mucus which can be detected 
via rheological studies and quartz crystal microbalance with dissipation monitoring (QCM-D) 
analysis. To have a closer look at molecular interactions between drug carrier and mucus 
small-angle neutron scattering (SANS) is an appropriate analysis technique. Moreover, 
different methods to determine particle diffusion in mucus such as the newly established 
Transwell diffusion system, rotating silicone tube technique, multiple-particle tracking (MPT) 
and diffusion NMR are summarized within this review. The explanations and discussed pros 
and cons of collated methods and techniques should provide a good starting point for all those 
looking forward to move in this interesting field.  
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1. Introduction 
Drug delivery systems have in many cases to cross several biological barriers in order to 
reach their site of action. One of these biological barriers is the dynamic semipermeable 
mucus layer. Mucus is a complex aqueous mixture of glycoproteins, lipids and salts covering 
many epithelial surfaces like the gastrointestinal tract (GI-tract), the vagina, the lung, the eye 
and various others in the human body. The viscous, elastic and sticky mucus layer that lines 
all these mucosal tissues protects the underlying epithelia by rapidly trapping and removing 
foreign excipients [1]. Drug delivery systems including micro- and nanoparticles are trapped 
in mucus layers by steric hindrances or adhesion processes. The limited permeability of 
particles through the mucus barrier leads in case of a rapid mucus turnover such as it is the 
case in the GI-tract to their rapid clearance from the delivery site and in many cases particles 
do not reach their target at all. In contrast, on mucosal tissues with a slow mucus turn over 
even mucoadhesive particles seem advantageous [2]. A profound knowledge about methods 
and techniques allowing a precise and accurate evaluation of mucus particle interactions is 
consequently substantial for the design and development of more efficient drug delivery 
systems.  
According to our knowledge different methods and techniques are used by various research 
groups to analyze the behavior of drug carriers in the mucus network. This review provides an 
overview about currently available as well as novel analytical methods for the evaluation of 
the fate of particulate delivery systems in mucus layers. Furthermore, it shall contribute to a 
harmonization of different techniques allowing a better comparison of results obtained by 
various research groups. During the last two years experts in the field of micro- and 
nanoparticulate drug delivery systems have intensively collaborated with experts in the field 
of mucus within the EU-project ALEXANDER [3]. They have utilized various mucus 
permeation techniques, have compared results obtained by different methods and techniques 
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with each other and improved these techniques due to their gained knowledge. Within this 
review their know-how and experience about various methods and techniques to study the 
mucus permeation and mucoadhesion behavior of micro- and nanoparticulate drug carrier 
systems is summarized. 
 
2. In vitro methods 
2.1 Intestinal mucus collection and purification 
For all particle mucus interaction studies the type of mucus and its preparation is crucial. 
Several sources of mucus have been used for permeation / transport studies ranging from 
native mucus gels, scraped gently from the surface of gastrointestinal mucosa of the pig [4, 5] 
to horse bronchial mucus [6]. Mucins are the major gel forming components of mucus gels 
which have a major role in governing the pore size in a mucus gel so many permeation studies 
have used mucins to mimic the mucus gel barrier [7, 8]. Unfortunately several groups have 
used mucin from porcine stomach type II from Sigma Aldrich. This preparation has been 
exposed to proteolytic action during isolation and has not been fully separated from co-
isolated contaminated proteins, lipids etc. The mucin structure has been irreversibly altered 
and will not form a gel when concentrated to levels x4 that present in the native mucus gel. 
Attempts have been made to purify sigma mucin [9] by ethanol precipitation, however, this 
will not restore its gel forming properties as much of the mucin polymeric structure (essential 
for gel formation) was lost by the action of the proteases. Due to the lack of rheological 
properties, attempts have been made to generate a biosimilar mucus using sigma pig mucin 
[10] by adding lipid, bovine serum albumin and poly acrylic acid. Although this results in 
similar rheological moduli (e.g. G’ and G’’) to porcine intestinal mucus, the charge on the gel, 
its interactions and size filtering properties will be different. In order to isolate native mucins 
to use in permeation studies several purification methods have been used Li et al. [11] have 
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partially purified the mucin from pig stomach however, they used a method without steps 
taken to prevent proteolysis which would degrade the mucin leading to loss of gel forming 
properties.  
The most effective method for isolating native mucin involves solubilization in a proteolytic 
inhibitor cocktail followed by fractionation in a CsCl equilibrium density gradient [12, 13]. 
This method produces mucins which are still gel forming [14]. Other groups have included  
4 – 6 M guanidinium hydrochloride in the extraction solution and in the CsCl gradient [15, 
16]. The problem with this is that it is a chaotropic agent and will denature the mucins and 
reduce their ability to form a gel. Studies by Georgiades et al. have shown that GuHCl 
disassembles the semi dilute network structure of porcine gastric mucin solutions by 
unfolding proteins and disrupting non-covalent interactions [17]. In studies where it is 
necessary to visualize particles in a scraped mucus gel or the gel contains food particles and 
other debris, the gel can be cleaned up by gently stirring for one hour at 4 °C in sodium 
chloride (0.1M) (1:5 w/v mucus to sodium chloride) and then centrifuged (10,400g at 10 °C) 
for 2 hours. This procedure can be repeated several times to aid in the collection of visually 
clean mucus.  
Finally, studies can be carried out using mucus producing cell models e.g. HT29-MTX cell 
line [14] which allow measurement of permeation and uptake however there is a note of 
caution as these are cancer cell lines and therefore absorption properties may be different 
from normal and it is well documented that mucins produced by cancer cells have shorter 
carbohydrate chains [18] and this could alter the gel structure. 
 
2.2 Mucus nanoparticle interaction studies via zeta potential and particle 
size measurements 
Mucus main components  independently of its origin are glycoproteins, lipids, water, detached 
epithelial cells, electrolytes and bacteria, however, the exact composition may differ regulated 
  
6 
 
by its physiological or mechanical role [19]. The contact between negatively charged mucus 
and nanoparticulate drug delivery systems can influence the physico-chemical properties of 
such nanoparticles. To analyze these interactions different methods are available. One of these 
methods is based on an assay developed within the ALEXANDER project, where surface 
properties of charged nanoparticles are tested after incubation with intestinal mucus [13]. In 
brief, a nanoparticle suspension is mixed with diluted native mucus following an incubation 
period over 4 hour at 37 °C and 300 rpm. At predefined time points samples are analyzed 
relating to their change in particle size and zeta potential. These alterations in surface 
properties of nanoparticles after incubation in mucus should give information about a possible 
adsorption of mucus to the particles indicated by a change in zeta potential as well as an 
increase in particle size. Results should help to clarify transport phenomena [20].  
Pereira et al. could prove with this method that negatively charged nanoparticles exhibit in 
contrast to positively charged particles no physico-chemical modifications after incubation 
with mucus [13]. The positively charged chondroitin sulfate-chitosan nanoparticles instead 
showed an increase in particles size as well as a decrease of the zeta-potential over the 
experimental period. The negatively charged mucus might coat the positively charged 
particles with a layer owing to electrostatic interactions resulting in alterations of these 
particle physico-chemical properties.  
A study by Dawson et al. observed, after incubation of carboxylated polystyrene particles and 
cationic poly(D,L-lactic-co-glycolic)acid nanoparticles in pig gastric mucin, similar negative 
zeta-potentials for these two nanoparticle formulations [20]. The authors concluded that 
mucus components adsorb easily positively as well as negatively charged nanoparticles.  
In a study from Nafee et al. the interaction between solid lipid nanoparticles (SLNs) and 
mucin were investigated related to binding SLNs to superficial mucus [21]. If the particle size 
of SLNs did not change after incubation the research group concluded a lack of interaction 
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and therefore the possibility for the particles to penetrate through mucus. The negatively 
charged SLNs retained in particle size over the experimental period.  
Evaluating the mucoadhesion of polymers, Takeuchi et al. used the described technique the 
other way around [22]. Commercial available porcine mucin particles were suspended in 
buffer and mixed with various polymer solutions. The zeta potential of the mucin particles 
was evaluated relating to mucoadhesion of the polymers. They could demonstrate that the 
addition of several types of chitosan and Carbopol changed the zeta potential of the mucin 
particles; whereby the addition of hydroxylpropylmethylcellulose had no effect on the zeta 
potential. The incorporation of cationic chitosan to the negatively charged mucin particles 
converted the zeta potential of the mixture to less negative values according to the chitosan 
concentration. They suggested that chitosan as well as Carbopol polymers have a high affinity 
to the mucin particles [22]. Furthermore, this method can be used to assess the stability of 
nanoparticles in biological fluids containing various proteins and enzymes [23].  
 
2.3 Mucus nanoparticle interaction studies via rheological measurements 
An integrated structure of biopolymers describes the mucus at the chemical level [24]. The 
physical behavior of this structure is a complex non-Newtonian, thixotropic gel. According to 
shear stress mucus acts as a viscous liquid or an elastic solid. The rheological properties of 
mucus differ as a function of shear stress, time rate of shearing and length scale [24].  
Rheological synergism has been proposed as an in vitro parameter to determine the 
mucoadhesive properties of polymers: the higher the rheological synergism, the stronger the 
particle interactions with mucin [25].  
Barthelmes et al. for instance tested the interactions of thiolated and unmodified poly(acrylic 
acid) as well as chitosan nanoparticles with vesical mucin on a plate-plate combination 
rheometer [2]. After the addition of mucus to the particles, an immediate increase in viscosity 
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especially for cationic thiolated chitosan nanoparticles was observed. The increase in 
viscosity was based on disulfide bond formation between the free thiol groups on the particle 
surface and cysteine-rich subdomains of glycoproteins within the intravesical mucus layer. 
Müller et al. used rheological investigations to determine the capacity of proteolytic 
excipients to cleave mucoglycoproteins being responsible for the integrity of the mucus [26]. 
Mucolytic enzymes, such as papain, disintegrate the mucus resulting in a decrease of the 
viscoelastic properties of the mucus layer, which can be determined by rheological 
experiments. As illustrated in Fig. 1, they have proven that after 6 hours of incubation with 
mucus, nanoparticles containing papain on their surface led to a liquefaction of the mucus, 
whereas nanoparticles without papain retained a relative mucus viscosity of 70% [26]. 
 
2.4 Mucus permeation studies 
2.4.1 Transwell-Snapwell system  
Permeation studies across freshly excised tissue are commonly performed with Ussing 
chambers [27]. Norris et al. adapted the Ussing chamber system with Snapwell rings and 
filters obtaining a vertical layer for mucus between the donor and acceptor chambers as is 
illustrated in Fig. 2 [28]. The three compartment diffusion system is thereby based on a donor 
and acceptor compartment separated by a central compartment containing a vertical layer of 
mucus. The mucus layer is surrounded with two permeable filters attached to the Snapwell 
ring to allow particles to permeate through the mucus. Modified Transwell-Snapwell diffusion 
chambers  were used from Müller et al. [26]. Both chambers containing a volume of 2 ml and 
a diffusion area of 2.14 cm2 are used to analyze the transport of labeled nanoparticles in 
mucus. The central compartment surrounded with two permeable polycarbonate filters is 
filled with 100 µl of freshly prepared natural mucus, attached to the Snapwell ring located 
between the donor and acceptor compartment. The diffusion chamber system is kept in an 
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incubator at 37°C for the experimental period and the diffused content of particles or drugs 
can be analyzed by spectrophotometry or chromatography.  
A study performed by Müller et al. utilizing this system demonstrated that the immobilization 
of the mucolytic enzyme papain on the poly(acrylic acid) nanoparticle surface had a 
significant influence on the particle transport across porcine mucus by cleavage of 
mucoglycoprotein substructures [26, 29]. The mucolytic enzyme modification of poly(acrylic 
acid) nanoparticles led to a 3.0-fold increased diffusion rate in comparison to unmodified 
poly(acrylic acid) nanoparticles.  
Furthermore, Laffleur et al. could demonstrate with this system that ‘slippery’ neutral 
nanoparticles prepared via ionic interaction between the anionic polymer poly(acrylic) acid 
and the cationic polymer poly(allylamine) exhibited a high diffusion efficiency [30]. The 
neutral nanoparticles were compared with poly(allylamine) nanoparticles and poly(acrylic 
acid) nanoparticles prepared by ionic gelation with tripolyphosphate and calcium ions, 
respectively.  
However, the central compartment of the Transwell-Snapwell system containing the vertical 
mucus layer is separated from the donor and the acceptor compartment by filters [28]. Due to 
the separation of the mucus layer from the donor chamber the Transwell Snapwell diffusion 
system has an additional barrier for particles compared to the human gastrointestinal passage. 
This circumstance is a main drawback of this method as a direct contact of particles with the 
mucus layer is avoided via the permeable filter and therefore the simulation of the in vivo 
situation is limited.  
 
2.4.2 Transwell diffusion system 
One system to determine mucus diffusion is the Side-by-Side® diffusion apparatus consisting 
one donor and one receiver as well as a custom membrane holder [31]. The membrane holder 
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is placed between the two compartments containing the mucus separated between two drug-
permeable membranes [19]. In contrast to the Side-by-Side® diffusion apparatus and the 
Transwell Snapwell system, a novel established method to study the diffusion in mucus is the 
Transwell diffusion system, a two compartment system [32]. A 24-well plate represents the 
acceptor compartment and additional 24 inserts the donor compartments, which are separated 
from each other by a membrane covered with 50 mg of fresh mucus as it is illustrated in Fig. 
3. This membrane, occupying a surface of 33.6 mm2, is suitable to spread the mucus on its 
surface, but impermeable for the mucus and allows drugs or particles to permeate. Samples 
can be taken from the acceptor chamber at predetermined time points and the diffused content 
of particles or drugs is analyzed by spectrophotometry or chromatography. 
Friedl et al. have already established this system with self-emulsifying drug delivery systems 
(SNEDDS) within a sufficient experimental runtime over 4 hours [32]. They demonstrated 
that the particle size of nanoemulsion correlates with the permeation rate. Furthermore, they 
demonstrated a significant influence of single excipients such as Cremophor RH 40 and 
Triacetin on the mucus diffusion of SNEDDS. As shown in Fig. 4, formulations consisting of 
10, 20 and 40% of Triacetin resulted in a continuous improvement of particle permeation 
according to the increasing amounts of the excipient. A 2-fold enhancement could be observed 
for SNEDDS consisting of 40% of Triacetin compared to the Triacetin-free control.  
Groo et al. tested the diffusion of different formulations of paclitaxel loaded lipid 
nanocapsules (LNCs) through pig gastrointestinal mucus using a similar Transwell diffusion 
system [33]. This system contains Snapwell inserts with a membrane area of 1.12 cm2 and 50 
µl of mucus were used. Hence, the Snapwell inserts have a higher surface area as the 
explained Transwell system above. Groo et al. revealed that paclitaxel LNCs containing a 
positive charge or neutral surface and additional short propylene glycol chains on their surface 
were suitable to diffuse through the mucus [33]. 
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One advantage of using this newly established two compartment system is the application of 
samples directly on the surface of the mucus, which simulates much closer the in vivo 
situation. Thus, the direct interaction between mucus and drug delivery systems can be 
investigated. A second advantage of this system is the time saving process. Friedl et al. 
demonstrated a sufficient experimental runtime over 4 hours with a thin mucus layer [32]. In 
contrast, previous systems such as the three chamber Side-by-Side diffusion apparatus have 
long experimental durations of 15-20 hours owing to a comparatively large amount of mucus, 
fixed between donor and acceptor compartment [19, 31]. The use of a 24 Transwell plate and 
the short experimental duration established a fast comparison of different samples. 
Beyond these advantages, the system allows the usage of any kind of mucus as well as native, 
purified or synthetic mucus. As mucus layers cover various epithelial surfaces in humans their 
functionality greatly differs [19]. Lieleg et al., for instance, showed that the mucus according 
to the location in the body varies in pH [34]. Crater et al. in contrast, observed differences in 
the particle transport through purified mucus in comparison to the particle transport in crude 
mucus [35]. They assumed that the differences may be occurred through different mesh 
structures of the native and the purified mucus or a different composition of the two mucus 
layers and therefore results are highly depending on the purification protocol.  
Utilizing the described Transwell system, permeation of particles can be examined within 
different purified mucus samples, different located mucus layers or at different pH values at 
the same time. Especially for high-priced drugs an decreased volume of the two 
compartments is convenient as in the Transwell® diffusion system only 250 µl test solution in 
the donor chamber and 500 µl buffer solution in the acceptor chamber are sufficient [32]. A 
smaller acceptor compartment offers the opportunity to test lower drug amounts without using 
high sensitive and expensive analytic apparatus. This possibility to use the Transwell diffusion 
system with smaller or bigger inlets is another main advantage of this novel developed 
system. 
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2.5 Mucus diffusion studies: rotating silicone tube 
For a better understanding of particle transport through the mucus layer, a diffusion system 
relating to the depth of diffusion was investigated [36]. In brief, clean mucus was filled in 
silicon tubes of 60 mm length and 4 mm in diameter and closed on one end with a silicon cap. 
At the open end of the tube labeled particle suspensions were added and the silicone tube 
closed securely with a second silicon cap. All the tubes were kept under horizontal rotation (≈ 
50 rpm) in an incubator at 37°C. At the end of each experiment silicone tubes were frozen. 
For analyzing the depth of diffusion into the mucus layer, the frozen tubes were cut into slices 
of 2 mm in length, beginning with the end, where the particle suspension was added.  
Dünnhaupt et al. introduced this diffusion model to compare the penetration behavior of 
fluorescein diacetate (FDA) labeled unmodified as well as thiolated anionic and cationic 
polymeric nanoparticles. A deeper mucus diffusion behavior of anionic poly(acrylic acid) 
particles (PAA) in comparison to positively charged chitosan nanoparticles (CS) was 
confirmed with this diffusion model. The repulsion between the anionic moieties of the mucus 
layer and the negatively charged unmodified or modified poly(acrylic acid) nanoparticles led 
to deeper diffusion of the nanoparticles as illustrated in Fig. 5 [36].  
One advantage of developed diffusion method might be the possibility to obtain more detailed 
information about the diffusion rate of particles within the mucus. The segmentation of the 
mucus-filled silicone tubes clarifies the depth and quantifies the amount of diffused particles 
in the mucus layer. Therewith achieved results about the diffusion behavior of particles can be 
combined with other methods, where for example the amount of permeated particles is 
determined as mentioned above. Additionally, the developed diffusion system is suitable for 
testing nanoparticles in different kinds of mucus or gel layers [37]. The diffusion behavior of 
particles can be compared with mucus from different compartments of the body such as 
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gastrointestinal or cervical mucosa in the same experiment. Furthermore, the small size of 
these silicon tubes facilitates the assessment of 20 or more tubes simultaneously. The low 
material costs and the use of basic laboratory instruments such as a rotator or an incubator are 
further advantages of this method. Nevertheless, besides all these advantages one 
disadvantage of this system is the accurate filling of the silicone tubes to avoid the 
incorporation of air bubbles into the mucus layer, which influences the outcoming results. 
Furthermore, possible changes in the mucus structure caused by the rotating movement must 
be taken into account. 
 
2.6 Multiple particle tracking 
Multiple particle tracking (MPT) involves the video microscopy and post-acquisition analysis 
of time-resolved particle trajectories within the particular matrix under study, e.g. cell 
cytoplasm, mucus, etc. As a technique it allows for the dynamic measurement of the 
movement of individual particles within a heterogeneous matrix, and as such contrasts to 
static techniques which quantify only the bulk movement of particles. MPT is not only 
capable of the accurate individual assessment of the diffusion of hundreds of particles [38] but 
also provides ‘behavioral’ or qualitative information on the environment in which the particles 
are moving. In particular it can reveal information on particle-matrix interactions e.g. 
interactions of particles with mucin fibers or the steric trapping of particles within the mucus 
mesh network [39]. Such qualitative information is obtained through the more in-depth 
analysis of the time-resolved particle trajectories to determine the different modes of particle 
diffusion [40] (see also below). Hanes’ group have been prominent early pioneers in using 
MPT to assess particle diffusion through heterogeneous matrices [41]. The group 
subsequently applied the technique to understand and quantify particle, including nanoparticle 
(NP), transport through a range of heterogeneous biological samples [42, 43]. For example, 
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the group used MPT to study the transport of amine and carboxylated modified polystyrene 
NPs through the sputum of cystic fibrosis patients and relating the respected transport to the 
micro-viscosity and macro-viscosity characteristics of the sputum [44]. The group has also 
used MPT to quantify, for example, the intracellular transport of non-viral polyethylene-
imine/DNA nano-sized polyplexes [45].  
MPT involves the simultaneous capture of the movement of hundreds of individual particles 
within a particular matrix, the basic principles of which include: 
• Labeling of the particles with a fluorescent dye whose physico-chemical properties are 
appropriate for the particle under study, and which will provide for a high signal to noise 
ratio in the biological matrix under investigation. Issues such as high background auto-
fluorescence of the matrix itself can compromise image quality and particle tracking [46]. 
Although not essential, a confocal microscopy platform may allow for improved signal to 
noise data capture as more defined excitation and emission sources can be selected (see 
below). 
• Inoculation of particles within the matrix. Clearly the pre-experimental preparation of the 
matrix will impact the efficiency and effective distribution of particle inoculation. 
Similarly the concentration of the particle inoculum itself can cause particle aggregation 
within the matrix [47]. In mucus samples (0.5 g) we have found an inoculum of a 25 µl 
0.002% NP suspension to consistently lack aggregation problems. Particle distribution 
within the matrix also requires a period of equilibration following inoculation and prior to 
video capture of the experiment proper, e.g. typically mucus samples are equilibrated with 
particles at 37°C for 2 hours prior to experimentation. 
• Video-microscopy capture of particle movement within the matrix. This will involve 
maintenance of the matrix under appropriate physiological conditions, e.g. 37oC, and the 
use of a high speed camera to capture particle movements. Typically, camera speeds of  at 
least 30 frames per second are used with videos  generally 10-20 seconds in length; the 
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short collection periods are sufficient to collect robust data and help minimize sample 
degradation issues, e.g. as discussed for mucus [19].  
• The microscope itself maybe either standard wide-field epifluorescence or confocal. 
Nevertheless, for mucus samples particle movement is most commonly captured in 2-
dimensions (X-Y), principally due to the isotropic nature of the matrix, i.e. particle 
movement in X=Y=Z. Further, 2-dimensional capture avoids inaccuracies in subsequent 
data and trajectory analysis that may be introduced by the process of Z-sectioning through 
the sample.  
The basic principles involved the post-acquisition analysis of particle movement and particle 
trajectories include: 
• Use of appropriate software, e.g. Fiji ImageJ, which can track the video movements of the 
particles at resolutions as high as 5 nm [48]. The software converts the movement of each 
particle as captured by high-speed video microscopy into individual particle trajectories. 
Appropriate rules need to be applied to the analyses e.g. videos capturing particle 
movement in 2-dimensions should provide that any single particle eligible for analysis 
must remain within same X-Y plane throughout all frames of the entire video capture 
period.  
• The movement of particles is translated into individual particle trajectories which are 
initially represented as numeric pixel data. This data is then converted from pixels into 
metric distance based on the microscope and video capture settings. From this the inter-
frame distances moved by each particle in the X-Y plane are expressed as a squared 
displacement (SD). The mean square displacement (MSD) of one particle represents the 
geometric mean of the sum of all of that particle’s square displacements throughout its 
transport trajectory [49]. Typically in a single experiment MSD data is calculated for at 
least 120 particles of each NP species under study, and the average of these MSD values 
(ca. 120 values) represents an “ensemble mean square displacement” defined by <MSD>. 
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The Effective Diffusion Coefficient (Deff) of a particular NP species can then be 
determined by Deff = <MSD>/(4*frame rate), where 4 is a constant relating to a 2-
dimensional mode of video capture and the frame rate relates to the speed of video capture 
[50].  
A schematic presentation of the principle of particle tracking is given in Fig. 6.  
The MPT technique tracks the change in movement of each single particle as a function of 
time. Unlike particle diffusion in water, which is non-restrictive and unchangeable with time, 
particles will undergo varying degrees of hindrance during their diffusion through a polymeric 
gel matrix such as mucus. Here the mucin fibres are undergoing continuous association and 
disassociation and the network as a whole undergoes elastic behavior resulting in the 
formation and collapse of aqueous cages surrounded by mucin fibres [51]. As such there will 
be significant potential for particle-gel interactions within mucus the probability of which 
increases as a function of time [52]. Accordingly, how the diffusion of individual particle 
changes with time not only provides information on the kinetics of movement but also the 
nature of movement, e.g. changes in time from unrestricted to restricted movement, e.g. 
“pearl on string trajectory”, may be indicative of increased particle interactions with, or 
trapping within, the mucin network. Such interactions captured by MPT have helped reveal 
information on the structure of the mucus mesh network [39] and on mucus micro-rheology 
[24]. 
The analysis underpinning studies on the nature or mode of particle diffusion can be 
undertaken by calculating the <MSD> for each particle over successive time scales, with a 
change <MSD> over this time period revealing the mode of particle motion which is 
represented in the literature by an exponential anomalous (α) [53]. Particle transport in water 
is described as ‘freely diffusive’ and α is equal to 1, while in an accelerated mixing 
environment α can be greater than 1 with the movement described then as ‘active diffusion’. 
Particle diffusion in mucus is often restricted and the α value is less than 1 with diffusion then 
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generally described as ‘sub-diffusive’ [54] and where α values between 0.2 and 0.9 reflecting 
varying degrees of hindrance to particle movement [47]; particles with an α value of less than 
0.2 are considered to be completely immobilized. A nuance building of individual particle 
behavior within this analysis technique is established to draw conclusions concerning the 
distribution of diffusive properties of the entire particle population. Such information can 
provide a unique assessment the heterogeneity of particle movement and the presence of 
outlier sub-populations indicative of distinctive pathways of diffusion through the matrix [55]. 
In summary MPT allows for the dynamic measurement of the movement of individual 
particles and sub-populations within heterogeneous biological and non-biological matrices. 
The information it provides complements that obtained by static approaches to assess particle 
diffusion. The main technical challenge for any investigator wishing to use the approach will 
be their ability to undertake high-speed fluorescent video microscopy. 
 
2.7 QCM-D method 
QCM-D (quartz crystal microbalance with dissipation monitoring) is in effect a high 
resolution weighing device that senses mass deposition of less than 1 ng/cm2 [56]. The 
induced change of resonance frequency (f) due to mass adsorption on the quartz crystal is 
measured together with energy dissipation (D) in real time, which is then used to convert to 
other parameter output such as the adsorbed mass, thickness, and viscoelastic properties of the 
layer [57]. The experimental set up consists of a quartz disc sandwiched between a pair of 
electrodes and can be made to oscillate by applying an alternating current (AC) voltage. When 
a thin film is applied to the sensor the frequency (f) will decrease and if the film is rigid the 
decrease in frequency is proportional to the mass of the film. However, if it is a soft film like 
mucus/mucin it will not be in phase with the oscillation of the crystal (i.e. energy dissipation 
D) which is also a measure of viscoelasticity. If a polymer/nanoparticle is then applied and an 
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interaction takes place a large change in frequency will occur and the variation in 
viscoelasticity of the complex will cause a variation in D. The principle of this technique is 
shown in Fig 7. 
This technique can be adapted to study the interaction of polymers and nanoparticles with 
mucine. In detail, the QCM-D instrument is able to measure two things. 
First, the variation in quartz crystal resonance frequency (∆f), which is related with the mass 
uptake and release at the sensor surface can be measured. There are different approaches both 
for rigid (Sauerbrey equation) and flexible films to correlate the variation of frequency with 
the mass change [58]. Thus, the instrument can be calibrated for calculating the mass 
absorbed on the sensor.  
Secondly, the energy dissipation (∆D), which is related with the structure and viscoelasticity 
of the film, can be determined. Briefly, QCM-D measures the dissipation of energy by the 
system, which is the part of accumulated energy lost at each oscillation, after switching off the 
exciting electric field. When the film is rigid (air in Fig. 8), the oscillation decays very slowly. 
When the viscoelasticity of the film increases (for instance in an hydrogel water absorption) 
the decay is much faster (liquid in Fig. 8). In mucin-polymer nanoparticle interactions, it 
should be noted that the polymer and the nanoparticles when interact with the mucin modify 
its viscoelasticity, the monitoring of the dissipation (∆D) gives insights about the nature of 
this interaction. 
Moreover, sequential multi-frequency measurement (the frequencies corresponding to the 
harmonic frequencies of the crystal) is done in order to record the different overtones of the 
oscillating system. It is important to point out that each overtone has a specific penetration 
depth, and they are measuring the behavior at different depths of the attached film. From a 
practical point of view, the decay distance is the penetration depth of the frequency 
measurements in QCM-D experiments. It is the maximum recording distance. For a 5 MHz 
crystal in water, the maximum penetration depth is δ ≈ 250 nm. The sensor’s overtones have 
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higher frequencies, so the penetration depth will be shorter. This means that, as they are 
measuring at different depths of the deposited film, they can be used to record the film 
response in different points at the same time. This characteristic has been used to study how 
the polymer or the nanoparticles are interacting with the mucin film. If the polymer were only 
absorbed on mucin surface, the overtones response would be different. On the other hand a 
penetration that affects the whole mucin leads to similar overtones behavior. 
Chayed and Winnik studied that the interaction between porcine mucin (bovine submaxillary 
mucin) and mucoadhesive polymers-based nanoparticles by means of QCM-D, and 
demonstrated that QCM-D is a promising technique for studying the mucoadhesive properties 
of biopolymers [59]. Recently, Wiecinski et al. studied QCM-D can be used as a screening 
method of biodurability of toxic nanoparticles [60]. They suggested that the interaction of 
nanoparticles with commercial porcine gastric mucin (CPGM) could be a good model to 
understand the impact of nanoparticles in the body. 
Recently, in the frame work of the European Project Alexander a QCM-D based method has 
been optimized to study the interaction of polymers and nanocarriers with fresh porcine 
gastric mucin. More than 50 samples of nanocarriers designed for mucus permeation have 
been analyzed with this method. It is interesting to highlight that the method developed is able 
to discriminate between the ionic interaction of charged nanoparticles and polymers with the 
negative charged mucin, and the penetration of the samples through the mucin. Second, as it 
could be expected the cationic polymers are easily absorbed on the mucin surface, and can be 
quantified following the frequency decrease as stated. Moreover, the variation of Dissipation 
(D) allows discriminating between pure adsorption (e.g. chitosan), with real mucin 
permeation (e.g. thiolated cationic polymers). It should be noted that when the permeation is 
produced, the dissipation rapidly decreases and increases in a moment, and then remains 
constant. The dissipation overtones get closer but the frequency plots have no changes. 
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2.8 Small-angle neutron scattering method  
When investigating relationships between physical properties and molecular structure, the 
determination of molecular organization within complex systems is fundamental; small-angle 
neutron scattering (SANS) - a powerful, non-destructive technique that probes organizational 
structure on a 1-200 nm lengthscale - can be easily applied for the study of delicate biological 
materials, although most studies published to date have focused on mucin [61-65]. 
The first studies using SANS to investigate the structure of pig gastric mucin were published 
in 2002 by Hong et al. [61]. Hong et al. found that individual mucin chains in unbuffered 
aqueous solvents adopted a cylindrical structure with a cross-sectional radius of c.a. 23 nm 
and a length of 96 nm. They also observed that a core/shell structure was adopted, where the 
core was formed by the protein backbone and the shell by the radial sugar chains. The 
evolution of the chain structure with changes in pH was also investigated; at pH 7, the mucin 
chains where swollen whereas, at pH 2 the mucin behaved like polymer chains dispersed in a 
“theta” solvent confirming an increase in hydrophobic interactions. 
Waigh et al. found evidence of a highly organized structure, discussed in terms of polydomain 
nematic phases above some critical semi-dilute concentration, and polyglycan orientation 
under magnetic field at lower concentration [62]. They also determined the cross-sectional 
radius and length of the mucin, obtaining results in agreement with Hong et al. 
SANS was also used in combination with small-angle X-ray scattering (SAXS) to determine 
the structure of pig gastric mucin [63], the chain dimensions determined from this study were 
significantly different to previous studies, i.e. radius c.a. 3.6 nm and length c.a. 12.5 nm. 
Griffiths et al. used SANS, combined with diffusion NMR to study the structure and 
dynamics of pig gastric mucin and the effect of addition of synthetic polymers often used as 
drug carriers [65]. From SANS, they observed that pig gastric mucin contains hydrophobic 
domains of approximately 9 nm spread apart by ca. 80 nm as shown in Fig. 9. 
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Charged polymers such as polyamidoamine dendrimers (PAMAM) or polyethyleneimine had 
an effect on the spacing of these hydrophobic groups depending on the pH investigated as 
shown in Fig. 10, whereas the neutral poly(ethylene oxide) had little effect on the structure of 
mucin, regardless of pH. 
Georgiades et al. [64] recently focused their studies on purified gastric and duodenal mucin 
using SANS and SAXS techniques. They confirmed that mucin forms a gel network above the 
semi-dilute concentration, studying the gel formation as a function of pH - a decrease in pH 
leads to microphse separation of the gels. They also found the persistence length of both 
mucin types to be c.a. 8 nm. 
The structure of intestinal mucus (Imucus) rather than mucin, and the changes arising from the 
incubation of enzyme-conjugated nanoparticles has been recently investigated within the 
ALEXANDER project [66]. SANS revealed that the scattering from Imucus exhibited a strong 
Q-2.6 dependency, characteristic of a fractal-like structure of a dense gel network. The samples 
incubated with particles or enzymes surprisingly showed little change in scattering pattern 
revealing that the mucus network was unaffected by these enzymes or enzyme conjugated 
nanoparticles, at least on the lengthscale probed by the SANS technique i.e. 1- 400 nm.  
 
2.9 Diffusion NMR 
Diffusion NMR – formally termed pulsed-gradient spin-echo NMR (PGSE-NMR) – is 
perhaps a unique experimental approach applicable to multi-component or heterogeneous 
systems. PGSE-NMR - non-invasive, non-destructive and retaining the chemical specificity of 
NMR - enables the behavior the several components within such multi-component systems to 
be simultaneously extracted from a single experiment. Structural information is encoded into 
the diffusion coefficient, which decrease with an increase in molecular size and are a sensitive 
reflection of any binding or obstruction the diffusing specie experiences within the solution.  
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There have been relatively few studies of diffusion in mucin/mucus systems [67, 68]. Li et al. 
investigated the diffusion of bile salt and phospholipid aggregates (of varying concentration 
from 1-7g/dL) in mucin (2 wt %) [67, 68], interpreting the changes in aggregate diffusion in 
terms of the transport of dietary lipid and solubilized drug through the aqueous boundary 
layer of the intestinal tract. 
Lafitte at al. utilized the diffusion of poly(ethylene glycol) polymers (PEGs) spanning a 
molecular weight range 1020 g mol-1 < Mw < 716,500 g mol-1 through pig gastric mucin 
(PGM) (5 wt %) as a probe to understand the relative importance of pH, ionic strength and 
temperature on defining mucin gel structure [69]. They concluded that the structure of the 
mucin gel – as perceived by the stronger dependency on the PEG diffusion - was dominated 
by pH effects, compared with ionic strength and temperature effects. For example, it was 
found that intermediate molecular weight PEG displayed a slower diffusion at pH 4 compared 
to both pH 1 and 7. The increase in diffusion between pH 1 and 4 was due to the mucin 
network being less homogeneous at pH 1 compared with pH 4. More surprising was the fact 
that the diffusion of the PEGs was faster at pH 7 than at pH 4. Associated with the drop in the 
pH, is a change in the physicochemical characteristics of the mucin molecule, and therefore 
the dynamics of the gel, due to the evolving balance of electrostatic and hydrophobic 
interactions. This is manifest as a decrease in the flexibility of the PGM molecules within the 
network, and the emergence of stronger hydrophobic interactions due to the decreasing net 
charge on the mucin molecule. These interactions facilitate the diffusion of PEG of 
intermediate molecular weight but not the largest PEGs which are too sterically hindered. 
 
In a similar vein, the same research group investigated the transport in mucin and mucus 
systems of polysorbate 80 (PS-80), a non-ionic surfactant commonly used as an excipient in 
many pharmaceutical formulations [70]. The study highlighted the existence of two 
populations of PS-80 molecules within a single sample: a non-surface-active fraction that can 
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move freely in the system (PS-80free) and a surface-active fraction that forms micellar 
structures resulting in a slower diffusion in the bio-gel (PS-80mic). However, the reduced 
transport rate of PS-80 in mucin is not due to a specific interaction with mucin but to a simple 
interaction of the PS-80 with the mucin network. PS-80 contains fatty acid chains and long 
ethylene oxide chains and as such, they are expected to behave in a similar fashion to PEG, 
showing steric hindrance on diffusion processes in the mucin network. 
Upon addition of the cationic surfactant tetradecyltrimethylammonium chloride (TTAC) to 
the mixture of mucin and PS-80, the formation of mixed micelles between PS-80 and TTAC 
occurred [71]. Depending on the composition of the mixture, complex-formation led to 
precipitation. Diffusion NMR measurements demonstrated that at low concentrations of PS-
80, mixed PS-80, TTAC and mucin aggregates were formed, but an increase in PS-80 
concentration caused the dissolution of the precipitate, limiting the interactions between the 
mixed micelles and the mucin. 
Griffiths et al. examined the diffusion coefficient of a series of candidate drug carrier 
polymers as a function of mucin concentration by diffusion NMR [65]. Recasting their data as 
a relative diffusion coefficient (the diffusive rate of the candidate polymer in mucin solution 
normalized to the diffusive rate of the same polymer observed in the absence of mucin) was 
shown to be a useful method to screen polymer/mucin interactions. For “interacting” 
polymers, the relative diffusion coefficient was substantially slower in the presence of 
physiological amounts of mucin. These data and this novel presentation method, showed a 
complex (and polymer-specific) relationship with molecular weight – for non-interacting 
polymers, there was the expected “obstruction” inducing decrease in diffusion rate for the two 
PEGs (10 K and 100 K g mol-1) but for “interacting” polymers such as the PAMAM 
dendrimers, G2 and G4 (3,256 g mol-1 and 14,215 g mol-1 respectively), there was a 
negligible difference in the relative diffusion coefficient. Further and again reflecting the 
nature of the interaction, the mucin retards the diffusion of the two PAMAMs to a degree 
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comparable to the larger PEG, notwithstanding the latter’s much greater size. The greatest 
reduction is shown by the highly branched poly(ethylene imine) 25 K g mol-1 sample. These 
data reflect the complex interplay between obstruction-only behavior (PEG, e.g. the basis of 
PEGylation [72]) and obstruction plus binding to the mucin (PAMAM, PEI) where additional 
retardation arises due to the molecular characteristics of the polymer and the mucin. 
The effect of enzyme decorated nanoparticles as well as the equivalent bare particles on the 
self-diffusion coefficient of pig intestinal mucin has been investigated recently within the 
ALEXANDER project [66] to compliment the SANS study discussed earlier. The results 
demonstrated that the presence of (enzyme and) enzyme decorated particles increased the 
diffusion coefficient of mucin, indicating an enhanced mobility due to the pertubation of the 
stiff gel network, whereas bare nanoparticles did not affect the diffusion of the mucin. 
 
3. In vivo methods 
In order to forecast the behavior of drug delivery systems in vivo, experimental set-ups in 
vitro have to be close to the in vivo reality. 
Several research groups are performing in vivo studies to analyze the mucoadhesive and 
mucus penetration properties of nanoparticles in different mucus layers [2, 26, 73-80]. They 
focused on the fate of particulate drug delivery systems in mucus especially on their uptake 
into the epithelium of the GI-tract after oral administration [43]. Basset and Carne´ showed in 
early studies that the intestinal epithelium is a barrier which cannot be permeated by 
particulate drug delivery systems [81]. In cats, for instance, intestinal mucus surrounds 
particles of India ink to prevent direct contact with epithelial cells [75]. Furthermore, Gruber 
et al. have observed the effect of several particles on gastrointestinal mucus in dogs and 
demonstrated that particles were transformed into mucus-covered ‘slugs’ independently of 
their size, density or composition [76]. Additionally, comparable results were observed after 
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administration of two different types of microparticles to rats. Particles remained for an 
equivalent time in the rat intestine, but covered with mucus and withdrawn by the animals 
[77].  
Lamprecht et al. furthermore, investigated the bioadhesion in reference to particle sizes 
specific to inflamed colonic mucosa [78]. They examined the particle deposition in the mucus 
as well as the particle uptake into the tissue from rats after oral administration. They could 
verify a size dependency of particle deposition in the thicker mucus layer next to the 
inflammation. Examined particles with the smallest size (0.1 µm) had the highest binding 
capacity into the mucus. Submicron-sized carriers showed a promising target for treating 
inflammatory bowel disease due to a high deposition rate next to the inflamed colonic 
mucosal areas.  
Studies on the transport of various fluorescence labeled PEGylated nanoparticles (PEG-NPs) 
were examined by Yoncheva et al. utilizing optical microscopy of isolated tissue segments 
after oral administration to rats [79]. The received micrographs showed the presence of 
marker within the cells of intestinal villi. They assumed that a PEGylation of NPs can 
improve their uptake into the epithelial cells. Moreover, they could demonstrate that PEG-NPs 
rather interacted and bind directly with the cell surface than with mucus components. 
In several studies the ligated intestinal loop model is used to evaluate the uptake of 
nanocarriers [82-85]. After exposing the abdomen of anaesthetized animals, usually rats, loop 
of ileum was prepared via ligation. Samples containing a fluorescence labeled drug or carrier 
are administered via injection into these loops. At preassigned time points the animals were 
sacrificed and the loops treated for following investigation. The drug carriers may (i) remain 
in the intestinal lumen; (ii) trapped in mucus; (iii) or penetrate through the mucus layer 
reaching the epithelium [83].  
Jin et al. for instance used the ligated intestinal loops in vivo technique to investigate the 
transport of epithelium-targeting nanoparticles as an oral insulin carrier [83]. NPs prepared of 
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trimethyl chitosan chloride (TMC), conjugated and non-conjugated with globlet cell-targeting 
ligand (CSKSSDYQC peptide) showed different penetration profiles. Results demonstrated 
that unmodified TMC-NPs remained in lumen and were trapped in mucus. This circumstance 
was 2.2-folder higher than for conjugated TMC-NPs. Furthermore, the working group could 
demonstrate within this study that the CSKSSDYQC peptide conjugated TMC-NPs could 
improve the absorption of insulin.  
A study by Li et al. showed that the detained effect of mucus on the absorption of a drug 
incorporated into chitosan nanoparticles (CNP) was more pronounced than on the absorption 
of a drug from core shell corona nanolipoparticles (CSC) via ligated intestinal loops technique 
[85]. CSC, compared with CNP, penetrated deeply into villi after 2 hours experimental time 
observed via confocal microscope. Pretreated removal of mucus in the loops confirmed the 
trapping efficacy of the mucus to the CNP.  
Several in vivo studies were arranged in terms of mucoadhesion of drug carriers with a longer 
resistance time near the active side [2, 26, 80]. The turnover of mucus layers at various 
surfaces differs, whereby mucoadhesive drug carriers are powerful target-orientated systems.  
Müller et al., for instance, performed in vivo studies, which focused on the distribution of 
particles in the gastrointestinal tract. These studies should give an overview of promising 
mucoadhesive and mucus penetrating particles and were closer to the human system than an 
in vitro experiments [26]. Briefly, the mucoadhesive properties of papain-functionalized 
nanoparticles were observed within the gastrointestinal tract of 24 Sprague-Dawley rats. It 
could be demonstrated that the penetration into the mucus layer could be improved via the 
immobilization of the mucolytic enzyme papain on the surface of poly(acrylic acid) 
nanoparticles. This result is attributed to the content of remaining nanoparticles in the 
anatomical segments as shown in Fig. 11. For comparison reason a mixture of fluorescein 
diacetate (FDA) and mannitol was utilized.  
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Albrecht et al., for instance, evaluated the remaining FDA amount incorporated in 
polycarbophil-cysteine microparticles on rat intestinal mucosa after oral application [80]. 
Segments of the intestine were analyzed regarding the fluorescence marker on the mucosa 
after administration of FDA labeled microparticles encapsulated in newly developed Eutex 
(Eudragit L100-55 and latex) capsules as well as in conventional enteric-coated capsules. It 
could be demonstrated that microparticles administered in Eutex capsules adhered 
significantly longer to the intestinal mucosa than administered in conventional enteric-coated 
capsules.  
Within in vivo experiments performed by Barthelmes et al., the mucoadhesive properties of 
thiolated nanoparticles on intravesical mucosa were estimated [2]. For this purpose 
fluorescein diacetate loaded thiolated chitosan nanoparticles were administered to the urinary 
bladder of rats. After different incubation periods, the content of remained nanoparticles was 
deteceted. Barthelmes et al. could proven that thiolated chitosan nanoparticles had a 4-fold 
increased mucoadhesion compared to their unmodified ones.  
Takeuchi et al. evaluated the mucoadhesive properties of chitosan-loaded liposomes after oral 
administration to rats via confocal laser scanning microscopy [74]. Based on the higher 
detected chitosan-coated liposome amount in the mucus layer in contrast to non-coated 
liposomes they could confirm the mucoadhesive function of the coating process. 
 
4. Concluding remarks 
The mucus barrier is an effective barrier towards micro- and nanoparticulate drug carrier 
systems owing to its lower adhesive clearing layer. The diffusion through this mucus barrier is 
therefore a complex phenomenon. Within this review various methods and techniques to 
hurdle this barrier utilizing micro- and nanoparticulate drug carrier systems were summarized.  
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Mucus nanoparticle interaction studies via zeta potential, particle size and rheological 
measurements as well as QCM-D method and SANS technique are useful methods to 
investigate the interaction of nanoparticulate drug delivery systems with mucus layers. 
Furthermore, several techniques presented within this article are available to measure the 
diffusion of particles through mucosal systems. For instance, the Transwell-Snapwell method, 
the Transwell diffusion method, rotating silicone tube technique, multiple particle tracking 
and diffusion NMR are promising diffusion systems. An overview of all different methods 
and techniques presented within this review is provided in Tab. 1.  
A simple technique to verify particle-mucus interaction is given by particle size and zeta 
potential measurements. Not only for this technique, also for permeation studies via Snapwell 
and Transwell systems as well as the rotating tube method no expensive equipment is 
required. In contrast, the purchase of a diffractometer, pulsed-gradient spin-echo NMR 
spectrometer, rheometer as well as a high-speed fluorescent video microscope as primary 
apparatus represents a costly investigation.  
In particular, it is not necessary to label nanocarriers if measurements are performed via 
diffusion NMR, QCM-D method, SANS and rheology. For diffusion/movement experiments 
via the Transwell-Snapwell system, the Transwell diffusion system, rotating silicone tube 
technique and multiple-particle tracking technique a labeling step of particles is required in 
order to determine particles in the mucus.  
With regard to a short experimental time, the MPT is convenience to measure the microscopic 
motion of hundreds of particles within seconds. Penetration studies using Transwell-Snapwell 
system, Transwell diffusion system or rotating silicone tube technique require a longer 
experimental time. In addition, nanoparticle mucus interaction studies via particle size and 
rheological measurements are as well more time consuming. Differences between methods 
utilized to study particle diffusion in the mucus gel layer are based on the static and dynamic 
process. The MPT and the diffusion NMR allow dynamic measurement of the movement of 
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particles within a matrix, whereas Transwell-Snapwell system, Transwell diffusion system or 
rotating silicone tube technique are static measurements. For the detection of viscoelastic 
changes in mucus after addition of nanocarriers bearing mucolytic enzymes on their surface 
the rheometer and the QCM-D model are advantageous. Furthermore, the QCM-D model has 
the benefit to separate between particle mucus interaction and particle mucus penetration. The 
use of SANS measurements can give an insight of the relationship between physical 
properties and molecular structures of complex systems. MPT, as one of the presented 
diffusion methods, is suitable for the dynamic measurement of the movement of individual 
particles and sub-populations within heterogeneous biological and non-biological matrices. 
Additional, the MPT provides also information on interactions between particulate drug 
delivery systems and matrixes such as particle trapping within mucus. The diffusion behavior 
of multi-component unlabeled systems in mucus can be analyzed in a single experiment with 
the use of diffusion NMR technique. By use of the rotating tube technique the depth of 
diffused particles in the mucus layer can be clarified. Within this technique, but also for the 
Transwell diffusion system, different kinds of mucus can be tested in one experiment  
Overall, it could be shown that different convenient methods and techniques were already 
established to evaluate the interactions between mucus layers and particulate drug delivery 
systems, whereby each technique has its benefits and drawbacks. Nevertheless, it has to be 
considered that not every technique and method already used by various research groups is 
presented within this review. Therefore, the authors of this review make no claim to be 
complete. In conclusion, the behavior of drug carriers within mucus can be explained far 
better using several techniques and methods simultaneously. The combination of presented 
techniques and methods might help to improve the evaluation of novel drug delivery systems 
in mucus layers.  
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Figure captions 
Fig. 1: Comparison of proteolytic properties of enzyme formulations by determination of the 
decrease of mucus viscosity at pH 6.5. Fresh porcine intestinal mucus (x) was incubated with 
0.5% (w/v) PAA particles (○), papain (□), papain-g-PAA particles (■), papain-g-PAA + CYS-
OET particles (●). Indicated values represent mean ± SD of at least three experiments 
(adopted from Müller et al. [26]) 
 
Fig. 2: Modification of the Ussing chamber system with Snapwell rings. The mucus layer is 
surrounded with two permeable filters attached to the Snapwell ring and incorporated between 
the donor and the acceptor compartment (adopted from Norris et al. [28]) 
 
Fig. 3: A schematic presentation of the Transwell diffusion system; A: acceptor compartment; 
B: semipermeable membrane; C: mucus gel layer; D: donor compartment (adopted from 
Friedl et al. [32]) 
 
Fig. 4: Overview of diffused amount of model drug through mucus layer related to the impact 
of Triacetin. Indicated values are means of at least three experiments ± SD. (adopted from 
Friedl et al. [32]) 
 
Fig. 5: Distribution of FDA labeled particles in natural porcine intestinal mucus pH 6.5 tested 
in the silicone tubes. left diagram: unmodified poly(acrylic acid) particles (grey bars) and 
thiolated poly(acrylic acid) particles (black bars); right diagram: unmodified chitosan particles 
(grey bars) and thiolated chitosan particles (black bars) (adopted from Dünnhaupt et al. [36]) 
 
Fig 6: The movement of each particle (P) was video captured as individual particle 
trajectories (Figure 6A) over a minimum of 30 consecutive frames with the criterion that any 
individual particle tracked must display a continuous presence in the X-Y plane throughout 
the respective 30 sequential frames. For example P1 in (6A) above tracked from (Δt1) to 
(Δt30). The distance moved in the X-Y trajectory by each particle over a time interval (Δt), i.e. 
camera frame rate, is expressed as a squared displacement (SD) (Figure 6B), SD
 
 = (X∆t )2 + 
(Y∆t  )2 . A mean square displacement (MSD) for any single particle can then be calculated by 
MSD
 
= [ (X∆t )2 + (Y∆t  )2 ] (∆t n =1-30)  
 
Fig. 7: Scheme of the experiment described to study by QCM-D mucin interaction with 
nanoparticles. Only one overtone is represented 
 
Fig. 8: Scheme of the Quartz Crystal dissipation in two media, air and water (adopted from 
Rodahl et al.[58]) 
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Fig. 9: Illustration of mucin consisting hydrophobic globules linked by a glycosylated Spacer 
(reprinted with permission from Griffiths et al. [65]. Copyright 2010 American Chemical 
Society)  
 
Fig. 10: Illustration of 5 wt% mucin scattering at pH 7 and 37 °C in absence of 0.5 wt% 
PAMAM dendrimer G2.0 (closed circles) and in presence of 0.5 wt% PAMAM dendrimer 
G2.0 (open circles); (reprinted with permission from Griffiths et al. [65]. Copyright 2010 
American Chemical Society) 
 
Fig. 11: Illustration of the remained nanoparticles content in the mucosa of removed rat 
gastrointestinal tract segments after oral administration and 3 h of incubation. (adopted from 
Müller et al. [26]) 
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Table 
Tab. 1: Comparison of presented methods and techniques among each other (I.S. – particle-mucus 
interaction studies; P.S. – particle permeation studies; D.S. particle diffusion studies) 
  
I.S. via 
particle size 
and zeta 
potential 
measuremen
t 
I.S. via 
rheological 
measuremen
t 
QCM-D 
method 
SANS 
method 
P.S. via 
Transwell
-Snapwell 
system 
P.S. via 
Transwell 
diffusion 
system 
D.S. via 
rotating 
tube 
MPT 
method 
Diffusion 
NMR 
method 
Used 
technique 
within this 
review 
particle-
mucus 
interaction 
study 
particle-
mucus 
interaction 
study 
particle-
mucus 
interactio
n study 
particle-
mucus 
interaction 
study 
particle 
permeatio
n study 
particle 
permeatio
n study 
particle 
diffusion 
study 
particle 
diffusion 
study 
particle 
diffusion 
study 
Mainframe 
required no 
yes:rheomete
r 
yes: 
weighing 
device 
yes: 
diffractomete
r 
no no no 
yes: 
fluorescenc
e video 
microscop 
yes: NMR 
spectromete
r 
Additional 
apparatus 
required 
no no no 
yes: particle 
sizer 
yes: 
fluoromete
r 
yes: 
fluoromete
r 
yes: 
fluoromete
r 
no no 
Labeling of 
particles 
required 
no no no no yes yes yes yes no 
Experiment
al time long long medium   long long long short   
Kind of 
measuremen
t 
        static static static dynamic  dynamic 
Required 
sample 
amount 
high high high   high low low low   
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Graphical abstract 
 
Highlights 
• Methods to examine interactions between mucus layer and nanocarriers were depicted. 
• Methods to analyze particle diffusion in mucus were summarized. 
• The explanations allow a better comparison of obtained results. 
• The discussed pros and cons provide a good starting point in this research field. 
 
